Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DA032098 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Emory University | OTHER |
| University of Miami | OTHER |
| The Village South | OTHER |
| Grady Health System |
Not provided
Not provided
Not provided
Not provided
This study will evaluate the efficacy of an integrated "Retention Clinic" in achieving virologic suppression among HIV-infected cocaine (including crack) users by using a two-group randomized, prospective trial. A total of 360 HIV-infected individuals who report cocaine (including crack) use will be randomized across study sites. The primary hypothesis is that more participants randomized to the "Retention Clinic" will have undetectable viral load than will participants randomized to the treatment as usual group.
This study will evaluate the efficacy of an integrated "Retention Clinic" in achieving virologic suppression among HIV-infected cocaine (including crack) users by using a two-group randomized, prospective trial.
Participants will be randomized to one of two groups: 1) "Retention Clinic" group and 2) Treatment as Usual. The intervention content of these groups is briefly described below:
Retention Clinic (RC) Group: This group will receive comprehensive and integrated services from a Retention Clinic. Services include HIV primary care, substance abuse treatment and mental health services, as needed. Participants in this group will also receive hands-on assistance with navigating through the clinic and accessing these services from a patient navigator.
Treatment as Usual (TAU) Group: This group will receive no protocol directed intervention. They will get the standard retention services from their local clinic.
All participants will provide informed consent and will complete a baseline audio computer-assisted self-interview or ACASI focusing on drug use, mental health, demographics and socio-economic factors, HIV care, and drug treatment history as well as blood draws for viral load and CD4 count. Follow-up assessments consisting of both ACASI and blood draws in all groups will be collected at 6 and 12 months post-randomization. Medical records will be reviewed to document use of HIV care, drug treatment and mental health services during the study period.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy). |
|
| Treatment as Usual (TAU) | No Intervention | The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Retention Clinic | Behavioral | The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy). |
| Measure | Description | Time Frame |
|---|---|---|
| Virologic suppression | To evaluate the effectiveness of the integrated "Retention Clinic" in achieving virologic suppression (defined as having an HIV-1 viral load <200 copies/mL at 6 and 12 months) among HIV-infected cocaine (including crack) users | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Attendance to HIV Care Visits | To evaluate the effectiveness of the integrated care Retention Clinic in increasing attendance at HIV care visits. | 12 months |
| Adherence to HIV Treatment Regimens |
Not provided
Inclusion Criteria:
Participating individuals must:
(*)Site PI discretion will be used to assess whether or not the AIDS-defining illness is a good indicator of eligibility. For example, if a patient does not meet the CD4 and viral load criteria and does have an AIDS-defining illness, the Site PI will assess the AIDS-defining illness to determine whether or not the patient is a suitable candidate for the study.
(**)Per PI discretion, the urine toxicology screen may be administered as part of the screening process if the participant's self-report and/or medical record data renders him/her ineligible on the drug use criterion.
Exclusion Criteria:
Individuals will be excluded from study participation if they:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lisa R. Metsch, Ph.D. | Columbia University | Principal Investigator |
| Carlos del Rio, M.D. | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jackson Health System-Special Immunology Clinic | Miami | Florida | 33136 | United States | ||
| Grady Health System-Ponce De Leon Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40276720 | Derived | Metsch LR, Feaster DJ, Gooden LK, Pan Y, Parish CL, Waldrop D, Rodriguez A, Colasanti JA, Armstrong WS, Root C, Del Rio C, Castellon PC, Miller M, Pereyra MR. Project RETAIN: Providing Integrated Care for People With HIV Who Use Cocaine. Open Forum Infect Dis. 2025 Mar 3;12(4):ofaf104. doi: 10.1093/ofid/ofaf104. eCollection 2025 Apr. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D019966 | Substance-Related Disorders |
| D000076064 | Drug Misuse |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| OTHER |
| Jackson Health System | OTHER |
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
|
To evaluate the effectiveness of the integrated care Retention Clinic in increasing adherence to HIV treatment regimens.
| 12 months |
| Attendance to Substance Abuse Treatment | To evaluate the effectiveness of the integrated care Retention Clinic in increasing attendance at substance abuse treatment. | 12 months |
| Decreasing Substance Use | To evaluate the effectiveness of the integrated care Retention Clinic in decreasing substance use. | 12 months |
| Atlanta |
| Georgia |
| 30308 |
| United States |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |